A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

View Full Paper

Ask AI

Bookmark

No abstract yet

We only have this paper's title and publication details.

EudraCT: 2015-001719-11. ClinicalTrials.gov Identifier: NCT02508896.

No takes yet. Share an insight, caveat, or question.

Zeitlinger et al. (2021) studied this question.

View Full Paper

Ask AI

Bookmark